DiagnoCure said last week it sold its PCA3 prostate cancer biomarker assets to Hologic‘s (NSDQ:HOLX) subsidiary Gen-Probe for $4.7 million (C$6.5 million). The purchase is slated to include $4 million (C$5.5 million) in cash and the repurchase of 4.9 million series A convertible preferred shares of DiagnoCure held by Gen-Probe, valued at $744,229 (C$1 million). “The […]